These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30635808)
21. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW; Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288 [TBL] [Abstract][Full Text] [Related]
22. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ; Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946 [TBL] [Abstract][Full Text] [Related]
23. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA; Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481 [TBL] [Abstract][Full Text] [Related]
24. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Yao L; Sun J; Zhang J; He Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Breast Cancer Res Treat; 2016 Apr; 156(3):441-445. PubMed ID: 27033093 [TBL] [Abstract][Full Text] [Related]
25. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
26. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Friedlaender A; Vuilleumier A; Sandoval JL; Viassolo V; Chappuis PO; Labidi-Galy SI Swiss Med Wkly; 2023 Mar; 153():40055. PubMed ID: 37011610 [TBL] [Abstract][Full Text] [Related]
30. BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. Kotsopoulos J; Willows K; Trat S; Kim RH; Volenik A; Sun P; Narod SA; Boyd J; May T Int J Gynecol Cancer; 2018 Jan; 28(1):69-76. PubMed ID: 29194191 [TBL] [Abstract][Full Text] [Related]
31. Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. Lee IH; Lee SJ; Kim J; Lee YH; Chong GO; Kim JM; Lee J; Lee NY; Park SY; Hong DG; Chae YS Cancer Chemother Pharmacol; 2024 Jul; 94(1):103-108. PubMed ID: 38652271 [TBL] [Abstract][Full Text] [Related]
32. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450 [TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. Boni V; Pistilli B; Braña I; Shapiro GI; Trigo J; Moreno V; Castellano D; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Longo F; Zaman K; Antón A; Paredes A; Huidobro G; Subbiah V ESMO Open; 2022 Oct; 7(5):100571. PubMed ID: 36037567 [TBL] [Abstract][Full Text] [Related]
35. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Tomao F; Musacchio L; Di Mauro F; Boccia SM; Di Donato V; Giancotti A; Perniola G; Palaia I; Muzii L; Benedetti Panici P Gynecol Oncol; 2019 Jul; 154(1):138-143. PubMed ID: 31079832 [TBL] [Abstract][Full Text] [Related]
36. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Halpern N; Sonnenblick A; Uziely B; Divinsky L; Goldberg Y; Hamburger T; Peretz T; Kadouri L Int J Cancer; 2017 May; 140(9):2145-2149. PubMed ID: 28120435 [TBL] [Abstract][Full Text] [Related]
37. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602 [TBL] [Abstract][Full Text] [Related]
38. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533 [TBL] [Abstract][Full Text] [Related]
39. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785 [TBL] [Abstract][Full Text] [Related]
40. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]